Risk and Association of Specific HLA Alleles With Nintedanib‐Induced Gastrointestinal Adverse Reactions: A Discovery Study in an Italian Population
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70371 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Stefano Mocci und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Genetics, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Indoles, Gastrointestinal Diseases, HLA Antigens. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: e.INS-Ecosystem of Innovation for Next Generation Sardinia, Italian Ministry for Research and Education (MUR), National Recovery and Resilience Plan (NRRP).
Abstract (Originalsprache)
Idiopathic Pulmonary Fibrosis (IPF) is a progressive and fatal lung disease with limited treatment options. Nintedanib and pirfenidone are the only antifibrotic drugs approved by both the USA and European medicinal agencies, but their efficacy and tolerability remain concerns. This exploratory study investigates the association between genetic variation in the Major Histocompatibility Complex (MHC) region and adverse effects (AEs) of these therapies. HLA genotyping has been previously performed in a discovery cohort of 124 IPF Italian patients, with recorded drug‐related AEs. Logistic regression analysis using an additive model identified HLA‐C*06:02 as a significant risk factor, increasing the likelihood of AEs sixfold in nintedanib ‐treated patients ( p = 0.0043, OR = 6.54, 95% C.I. 1.80–23.75). Notably, gastrointestinal toxicity—the most common AE—was strongly associated with this allele ( p = 0.0005, OR = 11.85, 95% C.I. 2.94–47.71). These findings suggest a potential immune‐mediated mechanism involving IL‐23‐driven inflammation and underscore the importance of pharmacogenetic tools in tailoring antifibrotic therapy. Implementing genetic screening could help minimize AEs and improve patient outcomes. Larger studies are warranted to validate these associations and guide personalized treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Genetics, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
- Centre for Research University Services (CeSAR, Centro Servizi di Ateneo per la Ricerca), University of Cagliari, Cagliari, Italy.
- Medical Genetics, R. Binaghi Hospital, Cagliari, Italy.
- Pneumology Unit, R. Binaghi Hospital, Cagliari, Italy.
- Oncology and Molecular Pathology Unit, Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.
- Department of Biomedical Sciences, University of Sassari, Sassari, Sardinia, Italy.
ORCID-Profile: Stefano Mocci, Roberto Littera, Silvia Deidda, Andrea Perra, Matteo Floris, Sabrina Giglio
Förderung
- e.INS-Ecosystem of Innovation for Next Generation Sardinia
- Italian Ministry for Research and Education (MUR)
- National Recovery and Resilience Plan (NRRP)
- University of Cagliari
- Ministero dell'Università e della Ricerca
Zitieren
APA
Mocci, S., Littera, R., Deidda, S., Perra, A., Floris, M., & Giglio, S. (2025). Risk and Association of Specific HLA Alleles With Nintedanib‐Induced Gastrointestinal Adverse Reactions: A Discovery Study in an Italian Population. Clinical and Translational Science. https://doi.org/10.1111/cts.70371
Vancouver
Mocci S, Littera R, Deidda S, Perra A, Floris M, Giglio S. Risk and Association of Specific HLA Alleles With Nintedanib‐Induced Gastrointestinal Adverse Reactions: A Discovery Study in an Italian Population. Clinical and Translational Science. 2025. doi:10.1111/cts.70371
BibTeX
@article{Mocci2025,
author = {Mocci, Stefano and Littera, Roberto and Deidda, Silvia and Perra, Andrea and Floris, Matteo and Giglio, Sabrina},
title = {Risk and Association of Specific HLA Alleles With Nintedanib‐Induced Gastrointestinal Adverse Reactions: A Discovery Study in an Italian Population},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70371}
}
EUVIMED